Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
A Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations
- Conditions
- OTOF Gene MutationDFNB9DeafnessCongenital DeafnessEar DiseasesOtorhinolaryngologic DiseasesHearing Loss, SensorineuralHearing Disorders
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Sensorion
- Target Recruit Count
- 12
- Registration Number
- NCT06370351
- Locations
- 🇦🇺
Childrens Hospital Westmead, Westmead, Australia
🇫🇷Hopital Necker Enfants Malades, Paris, France
Cross-sectional and Prospective Study to Characterize Early-onset Presbycusis
- Conditions
- Sensorineural Hearing Loss, Bilateral
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Sensorion
- Target Recruit Count
- 100
- Registration Number
- NCT06354010
- Locations
- 🇺🇸
The University of South Florida Board of Trustees, Tampa, Florida, United States
🇫🇷CHU Gui de Chauliac, Montpellier, France
SENS-401 to Prevent the Ototoxicity induced by Cisplatin in Adult Subjects with a Neoplastic Disease
- Conditions
- Cisplatine induced hearing loss
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sensorion
- Target Recruit Count
- 48
- Registration Number
- 2024-511713-38-00
- Locations
- 🇫🇷
CHU Henri Mondor, Creteil, France
🇫🇷Centre Medico Chirurgical Ambroise Pare Hartmann, Neuilly-Sur-Seine, France
🇫🇷Hopital Europeen Georges Pompidou, Paris, France
Natural History in Children Up to 16 Years with Mild to Profound Hearing Loss Due to Mutations in GJB2 / OTOF Genes
- Conditions
- Sensorineural Hearing Loss, BilateralAUNB1DFNB1ADFNB9GJB2 Gene MutationCongenital DeafnessOTOF Gene Mutation
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Sensorion
- Target Recruit Count
- 180
- Registration Number
- NCT05402813
- Locations
- 🇫🇷
Necker Hospital, Paris, France
Evaluation of the Presence of SENS-401 in the Perilymph
- Conditions
- Hearing Loss
- Interventions
- Drug: SENS-401 (R-Azasetron Besylate)
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Sensorion
- Target Recruit Count
- 28
- Registration Number
- NCT05258773
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Bordeaux, Hôpital Pellegrin, Bordeaux, France
🇫🇷Centre Hospitalier Universitaire de Clermont-Ferrand - Hôpital Gabriel Montpied, Clermont-Ferrand, France
🇫🇷Centre Hospitalier Universitaire de Lille Hôpital Roger Salengro, Lille, France
- Prev
- 1
- 2
- Next
News
Sensorion Completes Patient Enrollment in Phase 2a Trial of SENS-401 for Cisplatin-Induced Hearing Loss Prevention
Sensorion has enrolled the final patient in its NOTOXIS Phase 2a trial evaluating SENS-401 for preventing hearing loss caused by cisplatin chemotherapy, with 47 patients randomized across treatment and control groups.
Sensorion's Audiogene Trial Completes First Cohort Enrollment for OTOF Gene-Mediated Hearing Loss
Sensorion has completed enrollment of the first cohort in its Phase I/II Audiogene trial, evaluating SENS-501 for OTOF gene-mediated hearing loss.
Sensorion's SENS-501 Shows Promise in Gene Therapy for OTOF-Related Hearing Loss
Sensorion's SENS-501 Audiogene trial treated its first patient, showing initial safety and behavioral changes, with cohort completion expected by year-end.